Delving into the Latest Updates on Monteplase (Genetical Recombination) with Synapse

Overview

Basic Info

Drug Type

Enzyme

Synonyms

MF-TPA, Monteplase, Monteplase (INN)

+ [7]

Target

PLG

Mechanism

PLG stimulants(Plasminogen stimulants)

Therapeutic Areas

Cardiovascular DiseasesRespiratory Diseases

Active Indication

Pulmonary EmbolismCoronary Thrombosis

Inactive Indication-

Originator Organization

Eisai Co., Ltd.

Active Organization

Eisai Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (10 Apr 1998),

Coronary Thrombosis

RegulationOrphan Drug (JP)

Login to view timeline

Gene Sequence

Sequence Code 616721265

Source: *****

Sequence Code 157637

Source: *****

Evaluating safety and efficacy of low dose monteplase and nicorandil injected before percutaneous coronary intervention on left ventricular wall motion in patients of acute myocardial infarction:a randomized study. - Injection of low dose monteplase and nicorandil before percutaneous coronary intervention in patients of acute myocardial infarction(SALMAN study).

Start Date01 Nov 1999

Sponsor / Collaborator-

100 Clinical Results associated with Monteplase (Genetical Recombination)

Login to view more data

100 Translational Medicine associated with Monteplase (Genetical Recombination)

Login to view more data

100 Patents (Medical) associated with Monteplase (Genetical Recombination)

Login to view more data

47

Literatures (Medical) associated with Monteplase (Genetical Recombination)

01 Sep 2024·International Journal of Biological Macromolecules

Investigating the mechanism of Zn cross-linking of chitin in a mycelium-based leather substitute and its performance evaluation

Article

Author: Wang, Xinde ; Li, Shenglong ; Lu, Wenhui ; Zhang, Xiaojing ; Cao, Shan ; Zhang, Yizhi ; Zhu, Deyi

Mycelium-based leather substitutes with a three-dimensional reticulated structure have attracted attention owing to the negative environmental impacts of natural and synthetic leather. This study utilised Ganoderma lucidum mycelium to prepare a mycelium-based leather substitute with zinc cross-linking (MF-Zn) and evaluated its physicochemical properties and sensory performance; the conventional Cr³⁺ tanning method was used as reference. Results demonstrated that Zn²⁺ and Cr³⁺ formed cross-links with the -OH and -NHOCH₃ groups in the polysaccharides of chitin, while Zn²⁺ selectively bonded to a fraction of -NH₂ groups in cystine and phenylalanine. The mycelium-based leather substitute with Zn cross-linking exhibited impressive tensile strength and tear strength of 7.0 MPa and 16.4 kN/m, respectively, while demonstrating desirable organoleptic properties. The free radical-scavenging capacity of MF-Zn was assessed, revealing a DPPH radical and hydroxyl radical scavenging rates of 39.4% and 52.7%, respectively. By successfully investigating the cross-linking mechanism of mycelial fibres with Zn²⁺ and obtaining the stabilised mycelium-based leather substitute, this study establishes a fundamental basis for the development of sustainable leather substitutes, meeting the requirements and facilitating significant advancements in low-carbon leather substitute production.

01 Jul 2024·Journal of Veterinary Internal Medicine

Pulmonary thrombotic pulmonary hypertension managed using antithrombotic and pulmonary vasodilator treatment

Article

Author: Teshima, Takahiro ; Saito, Takahiro ; Suzuki, Ryohei ; Yuchi, Yunosuke ; Satomi, Shuji ; Horikawa, Rina ; Matsumoto, Hirotaka

AbstractAn 8‐year‐old Leonberger receiving immunosuppressive treatment with clinical signs of acute dyspnea, cyanosis, and difficulty standing was referred to our institution (Day 1). Treatment including oxygen, clopidogrel, and low‐molecular‐weight heparin was initiated for suspected pulmonary thrombosis. However, exertional dyspnea persisted until Day 10, and increased tricuspid regurgitation velocity, pulmonary vascular resistance, and McConnell's signs also were observed. Thus, beraprost sodium was administered PO on Day 11 to treat suspected pulmonary hypertension. On Day 13, contrast‐enhanced computed tomography identified extensive contrast defects in the pulmonary arteries, and IV monteplase was administered on Days 14 and 18, with marked improvement in respiratory status and exertional dyspnea on Day 20. Right ventricular function and McConnell signs also improved, and tricuspid regurgitation velocity and pulmonary vascular resistance decreased. On Day 250, echocardiography indicated further improvement in pulmonary hypertension pathophysiology. The patient was still progressing well with antithrombotic and pulmonary vasodilator treatment 400 days later.

01 Nov 2022·The American Journal of Emergency Medicine

Endovascular thrombectomy using a stent retriever catheter for massive pulmonary thromboembolism

Author: Asari, Yasushi ; Kurihara, Yutaro ; Kitamura, Ryoichi ; Sato, Nobuhiro ; Ishizue, Naruya ; Ikeda, Yuki ; Kinoshita, Daisuke ; Maruhashi, Takaaki ; Ichiyama, Saaya

Acute massive pulmonary thromboembolism (PE) has a high mortality rate of 18%-65%. Along with anticoagulation and thrombolytic therapy, treatment may require a catheter-based thrombectomy or surgical thrombectomy. We report a case of pulmonary thromboembolism treated with a Stent Retriever (Trevo® NXT ProVue Retriever, Stryker, Kalamazoo, MI, USA), which is commonly used to treat stroke. An 81-year-old woman complained of back pain and was transported to our hospital after she became unconscious. Cardiopulmonary resuscitation was initiated before her arrival at the hospital; she returned to spontaneous circulation after arrival. After undergoing computed tomography (CT) scanning, she went into cardiac arrest again, and we established veno-arterial extracorporeal membrane oxygenation and performed catheter thrombectomy using a stent retriever. The left basilar pulmonary artery and the right middle pulmonary artery trunk were retrieved after the stent's deployment, and bilateral pulmonary arteries were confirmed to be reopened. A residual thrombus was present, and Monteplase was administered. A contrast-enhanced CT scan taken on day 15 following admission revealed that the thrombus had disappeared, and echocardiography revealed improved right ventricular dysfunction. The patient was transferred to another hospital on day 64 for rehabilitation. We report the first case of pulmonary artery thrombosis that was successfully recanalized by endovascular treatment with a stent retriever. The stent retriever may be useful as an endovascular treatment device for PE because it is easier to achieve recanalization using this method compared to conventional treatment methods.

100 Deals associated with Monteplase (Genetical Recombination)

Login to view more data